Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Enterprise Value (2016 - 2026)

Collegium Pharmaceutical has reported Enterprise Value over the past 11 years, most recently at -$251.1 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 162.76% year-over-year to -$251.1 million; the TTM value through Dec 2025 reached -$251.1 million, down 162.76%, while the annual FY2025 figure was -$251.1 million, 162.76% down from the prior year.
  • Enterprise Value for Q4 2025 was -$251.1 million at Collegium Pharmaceutical, up from -$285.9 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$95.6 million in Q4 2024 and troughed at -$325.5 million in Q2 2023.
  • A 5-year average of -$213.7 million and a median of -$200.3 million in 2021 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: plummeted 165.21% in 2023 and later skyrocketed 69.23% in 2024.
  • Year by year, Enterprise Value stood at -$186.4 million in 2021, then rose by 6.83% to -$173.7 million in 2022, then crashed by 78.8% to -$310.5 million in 2023, then skyrocketed by 69.23% to -$95.6 million in 2024, then plummeted by 162.76% to -$251.1 million in 2025.
  • Business Quant data shows Enterprise Value for COLL at -$251.1 million in Q4 2025, -$285.9 million in Q3 2025, and -$222.2 million in Q2 2025.